TY  - JOUR
AU  - Leonide, A.
AU  - Rüger, B.
AU  - Weber, A.
AU  - Meulenberg, W. A.
AU  - Ivers-Tiffée, E.
TI  - Impedance Study of Alternative (La,Sr)FeO3-and (La,Sr)(Co,Fe)O3- MIEC Cathode Compositions
JO  - Journal of the Electrochemical Society
VL  - 157
SN  - 0013-4651
CY  - Pennington, NJ
PB  - Electrochemical Society
M1  - PreJuSER-10137
SP  - B234 - B239
PY  - 2010
N1  - Funding by the Fuel Cell Research Alliance Baden-Wurttemberg (project 23-729.90 5/371) is gratefully acknowledged.
AB  - This open-label extension evaluated the long-term efficacy and tolerability of rufinamide in patients with Lennox-Gastaut syndrome (LGS) who had previously completed a 12-week double-blind study.In total, 124 patients (aged 4-37 years), receiving 1-3 concomitant antiepileptic drugs, were treated with rufinamide approximately 25-60 mg/kg/day. Efficacy was assessed by seizure frequency; tolerability by adverse events (AEs) and laboratory tests.Overall, patients were treated with rufinamide for a median (range) of 432 (10-1149) days. Reductions in seizure frequency were observed throughout the study; during the last 12 months of treatment, 41.0% and 47.9% of patients had > or = 50% reduction in total and tonic-atonic seizure frequency, respectively. The most common AEs were vomiting (30.6%) and pyrexia (25.8%).In this open-label extension, rufinamide appeared to be an effective long-term adjunctive therapy for the treatment of LGS-associated seizures in children and young adults.
LB  - PUB:(DE-HGF)16
UR  - <Go to ISI:>//WOS:000273222700026
DO  - DOI:10.1149/1.3265473
UR  - https://juser.fz-juelich.de/record/10137
ER  -